Sign in Register

Indication

HER2-positive gastric adenocarcinoma

HER2-positive gastric adenocarcinoma is a molecular subtype of stomach cancer that originates in the glandular epithelial cells of the gastric mucosa. Read more about HER2-positive gastric adenocarcinoma

13 drugs 12 manufacturers

Advertisement

Drugs that treat it

Common HER2-positive gastric adenocarcinoma therapies.

Showing 1–9 of 13 drugs

Filter & compare in the drug finder →Opens the drug finder with HER2-positive gastric adenocarcinoma preselected.

News & literature

Coming soon

Related codes

Coming soon

Related conditions & guidelines

Coming soon

About HER2-positive gastric adenocarcinoma.

HER2-positive gastric adenocarcinoma is a molecular subtype of stomach cancer that originates in the glandular epithelial cells of the gastric mucosa.

It affects the digestive system and is characterized by the amplification of the *ERBB2* gene, leading to excessive overexpression of the human epidermal growth factor receptor 2 (HER2) transmembrane tyrosine kinase receptor.

This abnormal receptor density activates downstream oncogenic signaling pathways, promoting dysregulated cell proliferation, survival, and a typically aggressive clinical course.

Tumor HER2 positivity is established via diagnostic pathology using standardized immunohistochemistry and in situ hybridization techniques.

Personalize your experience

Follow HER2-positive gastric adenocarcinoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it